Literature DB >> 30397403

Reproductive Factors, Steroid Receptor Status, and Tumour Markers of HER2-Positive Breast Cancer in Northern China.

Xiaoyan Yuan1, Xuezhen Song1, Min Jiang1, Qiujing Li2, Xiaodan Liu1, Mingyi Wang1.   

Abstract

BACKGROUND: Although China has a breast cancer incidence that surpasses all other cancer registries, there have been few reports to evaluate the relationships of reproductive history, steroid receptor status, and tumour markers with HER2 status of breast cancer. PATIENTS AND METHODS: This project included 274 primary invasive ductal breast cancer patients. Information concerning the reproductive factors and tumour characteristics of the patients had previously been collected. HER2 and steroid receptor status were detected in tumour tissues. Serum CEA, CA15-3, and CA125 levels were analyzed for all patients.
RESULTS: Younger age at menarche was observed in patients with HER2-positive than in those with HER2negative status (p = 0.03). Statistically significant differences were found between the HER2-positive group and HER2-negative group for estrogen receptor (ER) and progesterone receptor (PR) status (p < 0.01). Age of onset, other reproductive factors, tumour characteristics, and serum tumour marker level were not significantly different between those patients with HER2-positive and those with HER2-negative status.
CONCLUSION: We confirm that age at menarche may plausibly be differentially correlated with the risk of HER2-positive invasive ductal breast cancer because it is presumed to impact exposure to endogenous sex hormones. HER2 is inversely related to ER and PR in invasive ductal breast cancer patients of Northern China.

Entities:  

Keywords:  HER2; Invasive ductal breast cancer; Reproductive factors; Steroid receptors; Tumour markers

Year:  2009        PMID: 30397403      PMCID: PMC6206960          DOI: 10.1159/000236467

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  18 in total

1.  Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.

Authors:  M Ferrero-Poüs; K Hacène; C Bouchet; V Le Doussal; M Tubiana-Hulin; F Spyratos
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

Review 2.  Reproductive factors and breast cancer.

Authors:  J L Kelsey; M D Gammon; E M John
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

3.  Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.

Authors:  Michael F Press; Guido Sauter; Leslie Bernstein; Ivonne E Villalobos; Martina Mirlacher; Jian-Yuan Zhou; Rooba Wardeh; Yong-Tian Li; Roberta Guzman; Yanling Ma; Jane Sullivan-Halley; Angela Santiago; Jinha M Park; Alessandro Riva; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

Review 4.  Epidemiology of endocrine-related risk factors for breast cancer.

Authors:  Leslie Bernstein
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

5.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

6.  Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

Authors:  Caroline J Witton; Jonathan R Reeves; James J Going; Timothy G Cooke; John M S Bartlett
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

7.  Time trends in cancer mortality in China: 1987-1999.

Authors:  Ling Yang; Donald M Parkin; Liandi Li; Yude Chen
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

8.  Breast cancer and clinical utility of CA 15-3 and CEA.

Authors:  W Jäger; S Krämer; V Palapelas; L Norbert
Journal:  Scand J Clin Lab Invest Suppl       Date:  1995

Review 9.  Her2-positive breast cancer: herceptin and beyond.

Authors:  Windy Dean-Colomb; Francisco J Esteva
Journal:  Eur J Cancer       Date:  2008-11-18       Impact factor: 9.162

10.  Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.

Authors:  H Kunisue; J Kurebayashi; T Otsuki; C K Tang; M Kurosumi; S Yamamoto; K Tanaka; H Doihara; N Shimizu; H Sonoo
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.